scholarly journals The Association Between Fear of Cancer Recurrence and the Gut Microbiota in Breast Cancer Survivors (P05-030-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Ryo Okubo ◽  
Takayuki Kinoshita ◽  
Noriko Katsumata ◽  
Yasuhiro Uezono ◽  
Jinzhong Xiao ◽  
...  

Abstract Objectives Dysfunctional processing of fear memory may be involved in the pathophysiology of fear of cancer recurrence (FCR), which is cited as the major unmet psychological need of cancer survivors. Emerging evidence has shown that the microbiota-gut-brain (MGB) axis affects psychiatric disorders, including depressive and anxiety disorders, which are associated with fear memory (PMID: 29628046). We therefore hypothesized that the gut microbiota is associated with FCR in cancer survivors (PMID: 29628046). Methods This cross-sectional study enrolled women diagnosed with invasive breast cancer who were not currently undergoing chemotherapy. Fecal samples were obtained to assess the gut microbiota. FCR grade was assessed using the Concerns About Recurrence Scale (CARS). Results Mean age of the participants (n = 126) was 58 years; 47% had stage I disease. Multiple regression analysis with adjustment for possible confounders showed that the relative abundance of the Bacteroides genus (beta = 0.180, P = 0.03) was significantly and directly associated with FCR. In the 57 participants with a history of chemotherapy, higher FCR was associated with lower microbial diversity (P = 0.04), lower relative abundance of Firmicutes (P = 0.03) and higher relative abundance of Bacteroidetes (P = 0.04) at the phylum level, and higher relative abundance of Bacteroides (P < 0.01) and lower relative abundance of Lachnospiraceae.g (P = 0.03) and Ruminococcus (P = 0.02) at the genus level. Conclusions Our findings provide the first evidence of an association between the gut microbiota and FCR and suggest that chemotherapy-induced changes in gut microbiota can influence FCR. Further studies should examine the effects of the gut microbiota on FCR using a prospective design. Funding Sources This study was supported in-part by a donation from Morinaga Milk Industry Co. Ltd, grants from the Japan Society for the Promotion of Sciences and the Foundation for Promotion of Cancer Research.

2020 ◽  
Vol 85 ◽  
pp. 186-191 ◽  
Author(s):  
Ryo Okubo ◽  
Takayuki Kinoshita ◽  
Noriko Katsumata ◽  
Yasuhito Uezono ◽  
Jinzhong Xiao ◽  
...  

2021 ◽  
Vol 4 (3) ◽  
pp. 46
Author(s):  
Yohei Sasaki ◽  
Mina Honyashiki ◽  
Takayuki Kinoshita ◽  
Akira Matsui ◽  
Ayako Nakashoji ◽  
...  

The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).


Cancer ◽  
2021 ◽  
Author(s):  
Lidia Schapira ◽  
Yue Zheng ◽  
Shari I. Gelber ◽  
Philip Poorvu ◽  
Kathryn J. Ruddy ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Malwina Tuman ◽  
Kailey E. Roberts ◽  
Geoffrey Corner ◽  
Courtney Beard ◽  
Carol Fadalla ◽  
...  

Introduction: Fear of cancer recurrence (FCR) is a prevalent and persistent challenge that many cancer survivors endure. While the role of interpretation bias, a tendency to perceive ambiguous situations as threatening, has been established in the onset and maintenance of FCR, few studies have examined cancer-related interpretation bias specifically. Grounded in the cognitive formulation of FCR, the current study aimed to fill this gap by investigating the relationship between cancer-related interpretation bias, FCR, and somatic symptoms, and examining whether bias mediates the relationship between somatic symptoms and FCR.Materials and Methods: This study used baseline data from a randomized controlled trial of a cognitive bias modification intervention. Breast cancer survivors (n = 110) provided demographic and medical background information as well as self-report measures of FCR and severity of somatic symptoms. A computer-based assessment of interpretation bias was used to measure cancer-related interpretation bias on several bias indices: percentage of cancer-related threat endorsement, and percentage of benign endorsement; mean reaction time (RT) for threat, and mean RT for benign endorsement.Results: Higher threat endorsement was linked to higher Overall Fear and emerged as a mediator of the relationship between overall somatic symptoms and Overall Fear. We also found that older age was related to longer benign endorsement RT.Conclusion: This study contributes understanding of factors related to cancer-related interpretation bias and provides evidence that bias may influence the relationship between somatic symptoms and FCR in cancer survivors.


Sign in / Sign up

Export Citation Format

Share Document